Comparing disease burden of rare diseases with common medical conditions in china: evidence from a national online health survey in 2022

比较中国罕见病与常见病的疾病负担:来自2022年全国在线健康调查的证据

阅读:1

Abstract

BACKGROUND: This study aims to measure the health-related quality of life (HRQoL) impact of rare diseases (RDs) and eye diseases, chronic diseases, Helicobacter pylori infection, and to assess their disease burden in China. METHODS: A national online survey was conducted among 21,909 Chinese residents between June 20 and August 31, 2022. The four self-reported medical conditions were identified. HRQoL was measured using the five-level EuroQol five-dimensional questionnaire (EQ-5D-5L). Both the multiple linear and logistic regression models were adopted to assess their impacts on EQ-5D utility and VAS scores. The prevalence-based quality-adjusted life-year (QALY) loss was calculated for RDs and other medical conditions. For each condition, QALY loss was calculated for 100,000 persons in 1 year using the associated reduction in EQ-5D utility score estimated in regression analysis. RESULTS: The self-reported prevalence of RDs was 1.2%, and the prevalence of eye diseases, chronic diseases, and Helicobacter pylori infection (unsure and yes) was 46.6%, 25.9%, 25.1% and 3.8%, respectively. All conditions, except for unsure Helicobacter pylori infection, were associated with significantly reduced EQ-5D utility scores, and RDs had the most profound impact on the utility score (β = -0.117; 95% confidence interval (CI): -0.151,-0.083). Chronic disease had the largest annual QALY loss per 100,000 persons at -1036.0 (95% CI: -1139.6, -906.5), followed by eye diseases at -279.6 (95% CI: -466.0, -139.8), RDs at -140.4 (95% CI: -181.2, -99.6), Helicobacter pylori infection (yes) at -98.8 (95% CI: -140.6, -57.0), and Helicobacter pylori infection (unsure) at -75.3 (95% CI: -157.7, 25.1). CONCLUSION: RDs have severe impact on HRQOL among Chinese residents, leading to the disproportionate QALY loss at population-level compared to their low prevalence. Therefore, greater attention should be paid to RDs and effective treatment strategies need to be developed. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s13690-025-01825-8.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。